Israel’s Teva Pharmaceutical Tuesday launched an unsolicited bid to buy Mylan for $40.1 billion in a transaction that would create a behemoth in generic drugs.
Under the offer, Mylan shareholders would receive a premium of 37.7 percent compared with the Mylan stock price of $59.57 prior to its April 8 bid for Perrigo, Teva said.
Quick Look at the Facts and Figues
|Mylan||Teva Pharmaceutical Industrues|
|2014 Revenue||$ 7.6 Billion||$20.6 Billion|
|2014 Net Income||$ 929.4 Million||$ 3.1 Billion|
What if the deal works:
Combining Israel-based Teva, the world’s largest generic drug maker, with Mylan, the third largest, would create a company with nearly $30 billion in revenue and more than 400 drugs awaiting regulatory approval. Teva expects a merger would generate $2 billion in synergies and tax savings.